...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' (CHADS2 score=1): simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.
【24h】

Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' (CHADS2 score=1): simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice.

机译：在“中等风险”（CHADS2评分= 1）下抗凝治疗和房颤患者的中风风险：在现实生活中，简化中风风险评估和血栓预防。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atrial fibrillation (AF) is a common and increasingly important risk factor for stroke and thromboembolism. However, this risk is not homogeneous, many recognised risk factors have been used to formulate stroke risk stratification schemas for AF (1,2). These schemas have been used to categorise patients into 'low', 'moderate/intermediate' and 'high' risk strata, and the majority of guidelines recommend the use of oral anticoagulation (currently, the vitamin K antagonists, VKA) for high risk subjects, whilst aspirin is recommended for low risk subjects (3). For moderate/intermediate risk subjects, the guidelines recommend 'oral anticoagulation or aspirin' given the inconvenience and limitations of VKA, and the possibility that the net clinical benefit in this category between stroke prevention and the potential harm from bleeding allows a choice between the oral anticoagulants and aspirin.
机译：心房纤颤（AF）是中风和血栓栓塞的常见且日益重要的危险因素。但是，这种风险并不均一，许多公认的风险因素已被用于制定房颤的卒中风险分层方案（1,2）。这些方案已被用于将患者分为“低”，“中/中”和“高”危险等级，并且大多数指南建议对高风险受试者使用口服抗凝药（目前为维生素K拮抗剂，VKA） ，而阿司匹林则建议用于低风险受试者（3）。对于中/中度风险受试者，鉴于VKA的不便和局限性，指南建议使用“口服抗凝药或阿司匹林”，并且在中风预防和出血潜在危害之间的这一类别的临床净收益可能允许在口服和口服之间进行选择抗凝药和阿司匹林。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号